TUCSON, Ariz. (PRWEB) January 23, 2013
The Muscular Dystrophy Association (MDA) has launched a clinical research network that will provide an infrastructure for trials of new treatments for myotonic muscular dystrophy (MMD, also known as DM). The rapid pace of research in this disease was the impetus behind the development of the network.
Each center in the new network has a particular interest and expertise in MMD, and the centers are distributed across the United States to maximize opportunities for participation in studies. Neurologist Charles Thornton at the University of Rochester Medical Center is the overall principal investigator for the network.
There are five university-based centers with expertise in this disorder that make up the network. Their first task will be to determine the usual progression of myotonic dystrophy and the best ways to measure the response of the disease to experimental treatments now in the developmental pipeline.
The five centers are:
Stanford University School of Medicine, Stanford, Calif. | Director: John Day, M.D., Ph.D.
University of Florida College of Medicine, Gainesville, Fla. | Director: Tetsuo Ashizawa, M.D.
University of Kansas Medical Center Research Institute, Kansas City, Kan. | Director: Richard Barohn, M.D.
University of Rochester Medical Center, Rochester, N.Y. | Director: Charles Thornton, M.D.
Ohio State University Medical Center, Columbus, Ohio | Director: John Kissel, M.D.
Network a response to scientific progress
"Recent years have seen rapid progress in the development of molecularly targeted therapy for myotonic
Copyright©2012 Vocus, Inc.
All rights reserved